NCT00230893

Brief Summary

The primary objective is to examine the percentage of patients with PTSD who were prescribed an antipsychotic over the past seven years in the VA Network 7 (AL, GA, SC) and compare the percentage on an annual basis. We will also determine the type and dose of antipsychotics received. We hypothesize that there has been a significant increase in antipsychotic use, especially atypical antipsychotics, prescribed for patients with PTSD over the last 7 years

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
99

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jul 2005

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2005

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2005

Completed
28 days until next milestone

First Submitted

Initial submission to the registry

September 29, 2005

Completed
4 days until next milestone

First Posted

Study publicly available on registry

October 3, 2005

Completed
Last Updated

September 21, 2006

Status Verified

September 1, 2006

First QC Date

September 29, 2005

Last Update Submit

September 20, 2006

Conditions

Keywords

AntipsychoticsPTSDPost Traumatic Stress Disordermonotherapyadjunct therapy

Eligibility Criteria

Age19 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Male or female patients, any race or ethnic origin at least 19 years of age.
  • Patients with a diagnosis of PTSD
  • Treated with an antipsychotic as a monotherapy or adjunctive therapy
  • Patient must have been seen at a VA medical center or clinic within VISN 7 during the study period.

You may not qualify if:

  • Patients not diagnosed with PTSD
  • Not treated with an antipsychotic as a monotherapy or adjunctive therapy
  • Patients outside of Network 7
  • Patients with a diagnosis of schizophrenia, schizoaffective disorder, or bipolar disorder

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Tuscaloosa VA Medical Center

Tuscaloosa, Alabama, 35404, United States

Location

Related Publications (1)

  • Kozaric-Kovacic D, Pivac N, Muck-Seler D, Rothbaum BO. Risperidone in psychotic combat-related posttraumatic stress disorder: an open trial. J Clin Psychiatry. 2005 Jul;66(7):922-7. doi: 10.4088/jcp.v66n0716.

    PMID: 16013909BACKGROUND

MeSH Terms

Conditions

Stress Disorders, Post-Traumatic

Condition Hierarchy (Ancestors)

Stress Disorders, TraumaticTrauma and Stressor Related DisordersMental Disorders

Study Officials

  • Lori L. Davis, MD

    Tuscaloosa Veterans Affairs Medical Center

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
DEFINED POPULATION
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER

Study Record Dates

First Submitted

September 29, 2005

First Posted

October 3, 2005

Study Start

July 1, 2005

Study Completion

September 1, 2005

Last Updated

September 21, 2006

Record last verified: 2006-09

Locations